BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 172 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $160 | -41.4% | 22,609 | -41.8% | 0.02% | -52.9% |
Q2 2023 | $273 | -99.9% | 38,825 | +42.4% | 0.03% | +3.0% |
Q2 2022 | $288,000 | -1.7% | 27,257 | +51.3% | 0.03% | -5.7% |
Q1 2022 | $293,000 | -23.9% | 18,017 | -32.7% | 0.04% | -23.9% |
Q3 2021 | $385,000 | +296.9% | 26,774 | +32.0% | 0.05% | +206.7% |
Q2 2020 | $97,000 | -2.0% | 20,284 | -58.9% | 0.02% | -21.1% |
Q1 2020 | $99,000 | -18.9% | 49,335 | +207.7% | 0.02% | +11.8% |
Q3 2018 | $122,000 | -15.3% | 16,036 | -38.0% | 0.02% | -37.0% |
Q2 2017 | $144,000 | -57.3% | 25,885 | -35.6% | 0.03% | -65.8% |
Q1 2017 | $337,000 | +524.1% | 40,190 | +110.3% | 0.08% | +426.7% |
Q1 2016 | $54,000 | -74.9% | 19,107 | +32.7% | 0.02% | -80.0% |
Q2 2015 | $215,000 | – | 14,397 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 7,637,700 | $77,675,000 | 7.44% |
Burrage Capital Management LLC | 864,916 | $8,796,000 | 7.13% |
ORACLE INVESTMENT MANAGEMENT INC | 2,367,670 | $24,079,000 | 3.61% |
HealthCor Management, L.P. | 4,886,440 | $49,695,000 | 1.76% |
Ghost Tree Capital, LLC | 500,000 | $5,085,000 | 1.20% |
Integral Health Asset Management, LLC | 400,000 | $4,068,000 | 1.16% |
Lisanti Capital Growth, LLC | 472,520 | $4,806,000 | 0.62% |
Parkman Healthcare Partners LLC | 244,680 | $2,488,000 | 0.58% |
Baker Brothers Advisors | 12,710,818 | $129,269,000 | 0.56% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,605,380 | $26,497,000 | 0.56% |